ClinicalTrials.gg
DrugBiological

Relatlimab clinical trials

Also written BMS-986016.

studies test it
50
open now
14
in phase 3
4
first study started
2013

Counted the way a researcher would: Relatlimab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses relatlimab has had a first review. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the relatlimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
18 Mar 2022 · OPDUALAG · BLA 761234 (FDA, Drugs@FDA; in a combination)
European Union
15 Sept 2022 · Opdualag · EMEA/H/C/005481 (EMA; in a combination)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Relatlimab
35
Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer
7

Development codes

BMS-986016
26
BMS-986016-01
1

In one entry with another drug

Given together, or one or the other

Nivolumab + Relatlimab
5
Relatlimab + Nivolumab
2

Studies by the year they started

50 studies that test it; most in 2019 (8)

Studies that test relatlimab, by start year
YearStudies
20131
20141
20151
20163
20173
20184
20198
20202
20215
20226
20235
20246
20252
20263

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
11
Phase 2
40
Phase 3
4
Phase 4
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 19 · Other 31

Bristol-Myers Squibb (19) · National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (5) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Dan Zandberg (1) · Melanoma Institute Australia (1) · The Netherlands Cancer Institute (1)

Often tested with

Tested in the same studies.

Nivolumab (25) · Ipilimumab (11) · Linrodostat (3) · Dasatinib (2) · Sunitinib (2) · Nivolumab, relatlimab drug combination (2) · Rucaparib (2) · Adavosertib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Relatlimab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 6

Studies that test relatlimab.

Studies

Open first, then newest update. How each study uses relatlimab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 50

See all 50 studies that test relatlimab →

Tested with established drugs · 15 — they are given beside it
Tested in a combination · 35 — another drug in the study is under test too

Showing 20 of 35. See all 35 →

Given beside what is tested · 20 — usual care or a partner of the new treatment
As the comparator · 4 — what is tested is compared with relatlimab
Observed · 5 — patients on it are followed, or it is given outside a trial

Codes

What other systems call relatlimab · ClinicalTrials.gg INT001801

  • MeSH (NLM) C000721227relatlimabOne source ClinicalTrials.gov
  • UNII (FDA) AF75XOF6W3RELATLIMABConfirmed FDA, Wikidata
  • RxNorm 2596773One source FDA
  • Wikidata Q58315670relatlimabConfirmed FDA, Wikidata
  • NCI Thesaurus C111999RelatlimabOne source FDA
  • DrugBank DB14851One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion